Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Update: 2025-09-17
Description
Host: Ryan Quigley
A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
